Oral obesity drug becomes available through Amazon Pharmacy
Amazon announced Friday that it is now offering Novo Nordisk’s Wegovy weight loss pill through its digital pharmacy, expanding access to the newly launched oral version of the popular obesity drug.
Novo Nordisk began rolling out the pill form of Wegovy in the United States earlier this week. The starting dose is priced at $149 per month for cash-paying patients, while those with insurance coverage may pay as little as $25 a month.
Lower-priced pill enters a fast-growing market
The daily pill arrives with one of the lowest cash prices in the booming obesity and diabetes drug market, which has been dominated by costly weekly injections. Its availability on Amazon highlights Novo Nordisk’s push to reach patients beyond traditional pharmacy channels.
Amazon said eligible customers with insurance can pay as little as $25 for a one-month supply, while the cash-pay option will start at $149 a month.
Expansion through clinics and kiosks
In the coming weeks, Amazon plans to offer the Wegovy pill through prescription vending kiosks located in select One Medical clinics, further integrating its pharmacy services with in-person care.
Amazon launched Amazon Pharmacy in 2020 after acquiring online pharmacy PillPack in 2018. It later expanded into primary care with its acquisition of One Medical in 2022.
Amazon’s growing role in health care
The company has positioned its pharmacy service around fast delivery and price transparency, offering same-day prescription delivery to nearly half of U.S. consumers. While Amazon has not disclosed user numbers, analysts estimate the business could generate around $2 billion in annual revenue.
Amazon Pharmacy has also partnered with Weight Watchers to deliver weight loss medications and has collaborated with Eli Lilly to distribute certain prescriptions, including its obesity drug Zepbound.
Wider distribution and future competition
Beyond Amazon, the Wegovy pill is now available at more than 70,000 U.S. pharmacies such as CVS and Costco, as well as through telehealth providers including Ro, LifeMD, GoodRx and Novo Nordisk’s NovoCare Pharmacy.
Cash-paying patients will also be able to access the starting dose for $149 per month through President Donald Trump’s direct-to-consumer website, TrumpRx, under a deal reached last November.
Oral options could broaden obesity treatment
Health experts say pill-based treatments may expand access to obesity care, particularly for people who are uncomfortable with injections. A rival obesity pill from Eli Lilly is expected to receive regulatory approval later this year, increasing competition in the space.
